NERV
Minerva Neurosciences IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$224.16M
P/E Ratio
—
EPS
$-34.54
Beta
-0.21
52W High
$8.80
52W Low
$1.24
50-Day MA
$6.11
200-Day MA
$3.74
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
11.21
PEG Ratio
0.00
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of candidate products for the treatment of diseases of the central nervous system. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-5.76M |
| EBITDA | $-15.10M |
| Operating Margin | 0.00% |
| Return on Equity | -675.00% |
| Return on Assets | -14.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-3.25 |
| Price-to-Book | 2.68 |
| Price-to-Sales (TTM) | 1.87 |
| EV/Revenue | 0.0345 |
| EV/EBITDA | 1.01 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $43.27M |
| Float | $24.62M |
| % Insiders | 3.60% |
| % Institutions | 68.19% |
Analyst Ratings
Consensus ($7.25 target)
2
HoldData last updated: 4/8/2026